One year in review; Authors: V. Giorgi, S. Sirotti, M.E. Romano, D. Marotto, J.N. Ablin, F. Salaffi, P. Sarzi-Puttini

Review; Authors: P. Sarzi-Puttini, V. Giorgi, F. Atzeni, R. Gorla, E. Kosek, E.H. Choy, L. Bazzichi, W. Hauser, J.N. Ablin, V. Aloush, D. Buskila, H. Amital, J.A. Da Silva, S. Perrot, B. Morlion, E. Polati, V. Schweiger, S. Coaccioli, G. Varrassi, M. Di Franco, R. Torta, K.M. Øien Forseth, K. Mannerkorpi, F. Salaffi, M. Di Carlo, G. Cassisi, A. Batticciotto

One year in review; Authors: V. Giorgi, L. Bazzichi, A. Batticciotto, G. Pellegrino, M. Di Franco, S. Sirotti, F. Atzeni, A. Alciati, F. Salaffi, P. Sarzi Puttini

Purpose of Review: Fibromyalgia Syndrome (FMS) is a complex chronic pain condition characterized by widespread musculoskeletal pain and numerous other debilitating symptoms. The purpose of this review is to provide a comprehensive overview, based on everyday clinical practice, of the drugs presently employed in the treatment of FMS. Recent Findings: The treatment of FMS is based on a multimodal approach, with pharmacologic treatment being an essential pillar. The drugs used include tricyclic antidepressants, serotonin and noradrenaline reuptake inhibitors, other antidepressants, anticonvulsants, myorelaxants, and analgesics. The effectiveness of these medications varies, and the choice of drug often depends on the specific symptoms presented by the patient. Many drugs tend to either address only some domains of the complex FMS symptomatology or have a limited effect on pain. Summary: Each treatment option comes with potential side effects and risks that necessitate careful consideration. It may be beneficial to divide patients into clinical subpopulations, such as FMS with comorbid depression, for more effective treatment. Despite the complexities and challenges, the pharmacological treatment remains a crucial part for the management of FMS. This review aims to guide clinicians in prescribing pharmacological treatment to individuals with FMS.